Results 91 to 100 of about 1,320,970 (304)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Building biomedical materials layer-by-layer [PDF]

open access: yes, 2012
In this materials perspective, the promise of water based layer-by-layer (LbL) assembly as a means of generating drug-releasing surfaces for biomedical applications, from small molecule therapeutics to biologic drugs and nucleic acids, is examined ...
Hammond, Paula T
core   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

open access: yesMolecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad   +35 more
wiley   +1 more source

Recent advances in surface-functionalised photosensitive antibacterials with synergistic effects

open access: yesBiosurface and Biotribology, 2019
The alarm has been ringing over the gradually increasing drug-resistant bacteria, which calls for the development of safer antibacterial materials. Photosensitive antibacterials are considered as a promising alternative solution due to their unique light-
Peizi Liao   +5 more
doaj   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Different Techniques and Algorithms for Biomedical Signal Processing [PDF]

open access: yes, 2006
This paper is intended to give a broad overview of the complex area of biomedical and their use in signal processing. It contains sufficient theoretical materials to provide some understanding of the techniques involved for the researcher in the field ...
Salleh, Sh-Hussain
core  

Hydrogels based on collagen and fibrin - Frontiers and applications [PDF]

open access: yes, 2016
Hydrogels are a versatile tool for a multitude of applications in biomedical research and clinical practice. Especially collagen and fibrin hydrogels are distinguished by their excellent biocompatibility, natural capacity for cell adhesion and low ...
Baganz, Sabrina   +4 more
core   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Promises, facts and challenges for graphene in biomedical applications [PDF]

open access: yes, 2017
The graphene family has captured the interest and the imagination of an increasing number of scientists working in different fields, ranging from composites to flexible electronics.
Bianco, Alberto   +5 more
core   +3 more sources

Home - About - Disclaimer - Privacy